β-defensin production by human colonic plasma cells: A new look at plasma cells in ulcerative colitis

Inflammatory Bowel Diseases

Volumn 13, Issue 7, 2007, Pages 847-855

  Rahman, Arman ^a   Fahlgren, Anna ^a   Sitohy, Basel ^a   Baranov, Vladimir ^a   Zirakzadeh, Ali ^a   Hammarström, Sten ^a   Danielsson, Åke ^a   Hammarström, Marie Louise ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Crohn's colitis; Innate immunity; Intestine; Ultrastructure

Indexed keywords

ANTIBIOTIC AGENT; BETA DEFENSIN; SYNDECAN 1;

ADULT; ARTICLE; CELL TRANSPORT; CLINICAL ARTICLE; COLON; COLON MUCOSA; COLON SURGERY; CONTROLLED STUDY; CROHN DISEASE; CYTOPLASM VESICLE; FEMALE; GOLGI COMPLEX; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOELECTRON MICROSCOPY; IMMUNOFLUORESCENCE; IN SITU HYBRIDIZATION; LAMINA PROPRIA; MALE; PLASMA CELL; PLASMACYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ULCERATIVE COLITIS;

ADULT; AGED; AGED, 80 AND OVER; BETA-DEFENSINS; COLITIS, ULCERATIVE; COLON; CROHN DISEASE; FEMALE; HUMANS; IMMUNITY, NATURAL; IN SITU HYBRIDIZATION, FLUORESCENCE; INTESTINAL MUCOSA; MALE; MICROSCOPY, FLUORESCENCE; MICROSCOPY, IMMUNOELECTRON; MIDDLE AGED; PLASMA CELLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 34547620846     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20141     Document Type: Article

References (38)

1. Tibble JA, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology. 2002;123:450-460.
2. + plasma cells with frequent labeling of Ki-67 in corticosteroid-resistant active ulcerative colitis. Virchows Arch. 2006;448:412-421.
3. Brandtzaeg P, Johansen F-E. Mucosal B cells: phenotypic characteristics, transcriptional regulation, and homing properties. Immunol Rev. 2005;206:32-63.
4. Targan SR, Landers CJ, Cobb L, et al. Perinuclear anti-neutrophil cytoplasmic antibodies are spontaneously produced by mucosal B cells of ulcerative colitis patients. J Immunol. 1995;155:3262-3267.
5. Halstensen TS, Das KM, Brandtzaeg P. Epithelial deposits of immunoglobulin G1 and activated complement colocalise with 40kD putative autoantigen in ulcerative colitis. Gut. 1993;34:650-657.
6. Onuma EK, Amenta PS, Ramaswamy K, et al. Autoimmunity in ulcerative colitis (UC): a predominant mucosal B cell response against human tropmyosin isoform 5. Clin Exp Immunol. 2000;121:466-471.
7. Campieri M, Gionchetti P. Bacteria as the cause of ulcerative colitis. Gut. 2001;48:132-135.
8. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002;122:44-54.
9. Darfeuille-Michaud A, Boudeau J, Bulois P, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology. 2004;127:412-421.
10. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev. 2003;3:710-720.
11. Selsted ME, Ouellette AJ. Mammalian defensins in the antimicrobial immune response. Nat Immunol. 2005;6:551-557.
12. Lehrer RI. Multispecific myeloid defensins. Curr Opin Hematol. 2007; 14:16-21.
13. Schutte BC, Mitros JP, Bartlett JA, et al. Discovery of five conserved beta-defensin gene clusters using a computational search strategy. Proc Natl Acad Sci U S A. 2002;99:2129-2133.
14. Aldred PM, Hollox EJ, Armour JA. Copy number polymorphism and expression level variation of the human alpha-defensin genes DEFA1 and DEFA3. Hum Mol Genet. 2005;14:2045-2052.
15. Linzmeier RM, Ganz T. Human defensingene copy number polymorphisms: comprehensive analysis of independent variation in alpha- and beta-defensin regions at 8p22-p23. Genomics. 2005;86:423-430.
16. Pazgier M, Hoover DM, Yang D, et al. Human beta-defensins. Cell Mol Life Sci. 2006;63:1294-1313.
17. O'Neil DA, Porter EM, Elewaut D, et al. Expression and regulation of the human beta-defensin hBD-1 and hBD-2 in intestinal epithelium. J. Immunol. 1999;163:6718-6724.
18. Cunliffe RN, Rose FR, Keyte J, et al. Human defensin 5 is stored in precursor form in normal Paneth cells and is expressed by some villous epithelial cells and by metaplastic Paneth cells in the colon in inflammatory bowel disease. Gut. 2001;48:176-185.
19. Fahlgren A, Hammarstrom S, Danielsson Å, et al. Increased expression of antimicrobial peptides and lysozyme in colonic epithelial cells of patients with ulcerative colitis. Clin Exp Immunol. 2003;131:90-101.
20. Fahlgren A, Hammarstrom S, Danielsson Å, et al. β-Defensin-3 and -4 in intestinal epithelial cells display increased mRNA expression in ulcerative colitis. Clin Exp Immunol. 2004;137:379-385.
21. Wehkamp J, Fellermann K, Herrlinger KR, et al. Human beta-defensin 2 but not beta defensin 1 is expressed preferentially in colon mucosa of inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2002;14: 745-752.
22. Wehkamp J, Harder J, Weichenthal M, et al. Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2003;9:215-223.
23. Fellermann K, Wehkamp J, Herrlinger KR, et al. Crohn's disease: a defensin deficiency syndrome? Eur J Gastroenterol Hepatol. 2003;15: 627-634.
24. Wehkamp J, Schauber J, Stange EF. Defensins and cathelicidins in gastrointestinal infections. Curr Opin Gastroenterol. 2007;23:32-38.
25. Nilsson K, Bennich H, Johansson SG, et al. Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin Exp Immunol. 1970;7:477-489.
26. Panoskaltsis-Mortari A, Bucy RP. In situ hybridization with digoxigenin-labeled RNA probes: facts and artifacts. Biotechniques. 1995;18: 300-307.
27. Weibel ER. Point counting methods. In: Weibel ER, ed. Stereological methods. Practical methods for biological morphometry, vol. 1. London: Academic Press; 1979:101-161.
28. Yeung MM, Melgar S, Baranov V, et al. Characterisation of mucosal lymphoid aggregates in ulcerative colitis: immune cell phenotype and TcR-gammadelta expression. Gut. 2000;47:215-227.
29. Nostrant TT, Kumar NB, Appelman HD, et al. Histopathology differentiates acute self-limited colitis from ulcerative colitis. Gastroenterology. 1987;92:318-328.
30. Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histological parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001;120:13-20.
31. Drexler HG, Matsuo Y. Malignant hematopoietic cell lines: in vitro models for study of multiple myeloma and plasma cell leukemia. Leukemia Res. 2000;24:681-703.
32. Bohnhorst J, Rasmussen T, Moen SH, et al. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia. 2006; 20:1138-1144.
33. Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammapathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002;99:1745-1757.
34. Hedvat CV, Comenzo RL, Teruya-Feldstein J, et al. Insight in extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma. Br J Hematol. 2003;122:728-744.
35. Yang D, Biragyn A, Hoover DM, et al. Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu Rev Immunol. 2004;22:181-215.
36. Garcia JR, Jaumann F, Schulz S, et al. Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction. Cell Tissue Res. 2001;306:257-264.
37. Rugtveit J, Bakka A, Brandtzaeg P. Differential distribution of B7.1 (CD80) and B7.2 (CD86) costimulatory molecules on mucosal macrophage subsets in human inflammatory bowel disease. Clin Exp Immunol. 1997;110:104-113.
38. Harder J, Bartels J, Christophers E, et al. A peptide antibiotic from human skin. Nature. 1997;387:861.